IDEXX Laboratories, Inc. (IDXX) – What Are Researchers Saying About This Stock?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) has received a consensus rating of “Moderate Buy” from the ten ratings firms that are currently covering the firm, Marketbeat reports. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $747.00.

A number of analysts have weighed in on the stock. Barclays decreased their target price on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. Citigroup raised their price objective on IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday. UBS Group upped their target price on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Finally, Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th.

IDEXX Laboratories Trading Up 0.9%

Shares of IDEXX Laboratories stock opened at $518.00 on Monday. The firm has a market capitalization of $40.81 billion, a PE ratio of 36.43, a price-to-earnings-growth ratio of 2.74 and a beta of 1.55. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The firm’s 50 day moving average is $538.96 and its 200 day moving average is $553.07. IDEXX Laboratories has a 1 year low of $500.61 and a 1 year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, beating the consensus estimate of $3.94 by $0.33. The business had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The firm’s revenue was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Equities research analysts forecast that IDEXX Laboratories will post 14.81 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $532.08, for a total value of $1,172,172.24. Following the completion of the transaction, the director owned 9,568 shares of the company’s stock, valued at $5,090,941.44. This represents a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.79% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On IDEXX Laboratories

A number of institutional investors have recently added to or reduced their stakes in IDXX. Schaper Benz & Wise Investment Counsel Inc. WI raised its position in IDEXX Laboratories by 1.4% during the 3rd quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 49,884 shares of the company’s stock worth $26,049,000 after purchasing an additional 678 shares during the last quarter. Lincoln Capital LLC grew its position in shares of IDEXX Laboratories by 0.9% in the 3rd quarter. Lincoln Capital LLC now owns 3,016 shares of the company’s stock valued at $1,589,000 after buying an additional 26 shares during the last quarter. Wedmont Private Capital grew its position in shares of IDEXX Laboratories by 13.7% in the 3rd quarter. Wedmont Private Capital now owns 3,509 shares of the company’s stock valued at $1,801,000 after buying an additional 423 shares during the last quarter. WoodTrust Financial Corp acquired a new stake in shares of IDEXX Laboratories in the third quarter valued at about $6,197,000. Finally, GAMMA Investing LLC raised its position in shares of IDEXX Laboratories by 1.8% during the third quarter. GAMMA Investing LLC now owns 3,357 shares of the company’s stock worth $1,753,000 after acquiring an additional 60 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.

IDEXX’s companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.